Compare Bill.com Holdings Inc (BILL) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bill.com Holdings Inc vs Merck & Co., Inc. — how do they compare? Bill.com Holdings Inc trades at $49.32 (market cap $4.93B), while Merck & Co., Inc. trades at $130.93 (market cap $321.77B). The key difference: Merck & Co., Inc. is far larger — about 65.3× Bill.com Holdings Inc's market cap, and Merck & Co., Inc. pays a 2.61% dividend while Bill.com Holdings Inc pays none. Which is the better fit depends on your goals.
| BILL | MRK | |
|---|---|---|
Market Cap | $4.93B | $321.77B |
Sector | Technology | Health |
52-Week High | $56.32 | $131.84 |
52-Week Low | $31.96 | $77.60 |
Enterprise Value | $4.64B | $368.53B |
Dividend Yield | — | 2.61% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BILL Holdings trades at $49.26, up 2.65% today, showing strong momentum with three consecutive earnings beats. The stock exhibits bullish technical signals with moving averages supporting upward movement, though RSI levels suggest potential overbought conditions. Fundamentally, revenue growth has accelerated from $642M in 2022 to $1.46B in 2025, with the company achieving positive net income for the first time. Recent leadership changes and operational efficiency initiatives, including a 30% workforce reduction, position the company for improved profitability.
The outlook remains positive with 56% analyst buy ratings and a consensus price target of $45.67, though current price exceeds this target. Key risks include high valuation multiples (P/E 213.91) and intense fintech competition. Upside catalysts include continued SMB adoption and AI-driven automation growth, while execution risks and market volatility present challenges for investors seeking exposure to the financial operations software sector.
Merck (MRK) trades at $130.9, up 1.81% today, with a bullish technical outlook supported by moving averages and a consensus analyst price target of $140.36. Recent earnings beats and a 72.97% gross margin highlight strong profitability, while the acquisition of Terns Pharmaceuticals aims to bolster its oncology pipeline. The stock faces headwinds from a high P/E ratio of 104.34 and fluctuating cash flows.
The outlook is positive with robust fundamentals and strategic M&A, but valuation concerns and competitive pressures in pharma pose risks. Upside is likely if earnings growth continues, though investors should monitor debt levels and integration of acquisitions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bill.com Holdings Inc
Bill.com Holdings Inc is a provider of cloud-based software that simplifies, digitizes, and automates financial operations for SMBs. Its artificial-intelligence enabled financial software platform used mostly to build connections between customers, suppliers, and clients. The company's platform generates and process invoices, streamline approvals, send and receive payments, sync with their accounting system, and manage their cash. The firm generates revenue through subscription and transaction fees.
Read more on BILL →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
